The funding will enable BII to expand its activities into new strategic areas and geographies, and support even more entrepreneurs and start-up-companies, thereby strengthening innovation in Denmark and Europe. The new funding frame runs from 2026 to 2035.

Over the coming years, BII expects to scale its activities by significantly increasing the number of start-ups supported each year. While supporting life science and biotech start-ups will remain key, the new long-term support from the Novo Nordisk Foundation enables BII to venture into new scientific and technological fields like AI and quantum.

This will prove instrumental in securing that even more science is translated into new companies, jobs and solutions benefitting people and our planet – and ultimately driving the growth and entrepreneurial culture that will benefit European competitiveness.

“We are giving BII the opportunity to expand its reach and further strengthen its position as a European powerhouse for innovation. This will prove instrumental in securing that even more science is translated into new companies, jobs and solutions benefitting people and our planet – and ultimately driving the growth and entrepreneurial culture that will benefit European competitiveness,” says Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation.